1. Phylogeny  
   Tyrosine‐protein kinase JAK3 (UniProt ID P52333) belongs to the Janus kinase (JAK) family, which comprises four members in mammals (JAK1, JAK2, JAK3, and TYK2) that evolved early in metazoans and are conserved from invertebrates to vertebrates (yamaoka2004thejanuskinases pages 1-2, yeh1999thejanuskinase pages 1-3). Among its family members, JAK3 is distinct because its expression is largely restricted to hematopoietic lineages, particularly immune cells, whereas the other JAKs are more ubiquitously expressed; this tissue‐restricted expression reflects its specialized functions in cytokine receptor signaling in adaptive and innate immunity (yamaoka2004thejanuskinases pages 1-2). Phylogenetic analyses indicate that the JAK kinases share a common ancestor with a characteristic domain architecture that includes a FERM domain, an SH2-like domain, a catalytically impaired pseudokinase domain, and a catalytic kinase domain; the appearance of these domains coincides with the emergence of cytokine-mediated regulatory networks in higher metazoans (yeh1999thejanuskinase pages 1-3). In addition, the restricted expression pattern of JAK3 correlates with the evolution of the common gamma chain (γc) cytokine receptors, underscoring a coevolution of receptor–kinase pairs in immune system development (yamaoka2004thejanuskinases pages 2-3).
2. Reaction Catalyzed  
   JAK3 catalyzes the transfer of the γ-phosphate group from adenosine triphosphate (ATP) to specific tyrosine residues on its substrates, which include cytoplasmic tail motifs of cytokine receptors and signal transducer and activator of transcription (STAT) proteins; this reaction results in the formation of adenosine diphosphate (ADP) and a phosphorylated substrate (babon2014themolecularregulation pages 1-3). The phosphorylation event initiated by JAK3 is fundamental in the activation cascade of the JAK–STAT signaling pathway, thereby directly linking extracellular cytokine signals to transcriptional responses in the nucleus (babon2014themolecularregulation pages 1-3).
3. Cofactor Requirements  
   The catalytic activity of JAK3 is ATP-dependent and, as with most protein tyrosine kinases, requires divalent cations—most notably Mg²⁺—to coordinate the binding of ATP in its active site; these cofactors facilitate the proper orientation and transfer of the γ-phosphate group to the substrate (babon2014themolecularregulation pages 1-3, hall2010expressionpurificationcharacterization pages 1-2).
4. Substrate Specificity  
   JAK3 exhibits substrate specificity primarily toward tyrosine residues present within the intracellular domains of cytokine receptors that contain the common gamma chain, such as those for interleukins IL-2, IL-4, IL-7, IL-9, IL-15, and IL-21; these residues, once phosphorylated, serve as docking sites for STAT transcription factors (babon2014themolecularregulation pages 1-3, babon2014themolecularregulation pages 13-14). In addition, JAK3 phosphorylates STAT proteins directly, thereby facilitating their dimerization and subsequent translocation to the nucleus; the recognition of substrate sequences within both receptor tails and STATs is essential for the propagation of cytokine signaling cascades (babon2014themolecularregulation pages 13-14).
5. Structure  
   JAK3 is organized into several distinct functional domains. The amino-terminal region encompasses the FERM (band 4.1, ezrin, radixin, moesin) domain, which mediates interactions with the cytoplasmic regions of cytokine receptors; this domain is critical for the receptor-binding specificity observed in JAK3 (babon2014themolecularregulation pages 1-3, yamaoka2004thejanuskinases pages 2-3). Adjacent to the FERM domain is an SH2-like domain that, despite lacking some of the canonical features of classical SH2 domains, contributes to protein–protein interactions involved in receptor signaling (babon2014themolecularregulation pages 4-6). Central to the regulatory function of JAK3 is the pseudokinase domain (JH2), which, although catalytically impaired relative to canonical kinases, binds ATP and exerts an autoinhibitory effect upon the catalytic domain; this domain plays a crucial role in modulating the basal activity of the enzyme and can influence activation upon cytokine stimulation (babon2014themolecularregulation pages 4-6, vihinen2000molecularmodelingof pages 3-5). The carboxy-terminal kinase domain (JH1) houses the active site and is responsible for catalytic activity; it contains the activation loop with key tyrosine residues (e.g., Y980 and Y981) whose phosphorylation events regulate enzyme activation and substrate binding (babon2014themolecularregulation pages 1-3, vihinen2000molecularmodelingof pages 5-7). A unique structural feature of JAK3 is the presence of a conserved cysteine residue (C909) located near the ATP-binding pocket; this residue has been exploited in the development of selective covalent inhibitors that can distinguish JAK3 from other JAK family members (tan2015developmentofselective pages 3-4, kim2010nsc114792anovel pages 1-2). Crystallographic and biochemical studies, including high-resolution structures of the kinase domain in both nonphosphorylated and phosphorylated states, have provided further insight into the conformational dynamics of JAK3 and its regulatory mechanisms (hall2010expressionpurificationcharacterization pages 10-10).
6. Regulation  
   JAK3 activity is regulated through multiple mechanisms that ensure precise control of cytokine signaling. Activation is initiated by ligand binding to cytokine receptors, which are associated with JAK3; receptor dimerization or conformational changes trigger trans-phosphorylation of JAK3 on tyrosine residues within its activation loop, a necessary modification for full catalytic activation (babon2014themolecularregulation pages 1-3, tsui2011anewregulatory pages 7-8). The adjacent pseudokinase domain (JH2) exerts an autoinhibitory influence on the kinase domain (JH1) in the absence of receptor engagement, thereby preventing unwarranted activation; ATP binding to the pseudokinase domain further modulates this inhibitory activity and contributes to the regulation of both basal and cytokine-induced kinase activity (babon2014themolecularregulation pages 4-6, raivola2018hyperactivationofoncogenic pages 8-10). Negative regulation is also achieved via protein tyrosine phosphatases such as SHP-1, which dephosphorylate activated JAK3 and help to terminate the signaling response; in addition, suppressors of cytokine signaling (SOCS) proteins, although effective against other JAK family members, exhibit reduced inhibitory action on JAK3 due to distinct sequence variations in the kinase domain (babon2012suppressionofcytokine pages 2-4, wilks2008thejakkinases pages 9-9). Mutations that compromise the structural integrity of the pseudokinase domain or affect critical phosphorylation sites can lead to either loss-of-function, as observed in severe combined immunodeficiency (SCID), or gain-of-function, which is associated with hyperactivation and oncogenic transformation (chen2000complexeffectsof pages 8-9, raivola2018hyperactivationofoncogenic pages 4-7). Overall, the regulation of JAK3 is a balance between receptor-mediated activation, autoinhibitory control through its JH2 domain, and downstream deactivation by phosphatases, all of which contribute to the fidelity of cytokine signal transduction (tsui2011anewregulatory pages 7-8, babon2014themolecularregulation pages 3-4).
7. Function  
   JAK3 plays a pivotal role in the transduction of cytokine signals in hematopoietic and immune cells. Predominantly expressed in lymphoid tissues, JAK3 is physically associated with the common gamma chain (γc) shared by several interleukin receptors, such as IL-2, IL-4, IL-7, IL-9, IL-15, and IL-21 receptors; upon ligand binding, JAK3 is activated and phosphorylates tyrosine residues on the receptor cytoplasmic domains, thereby generating docking sites for STAT proteins (babon2014themolecularregulation pages 13-14, yamaoka2004thejanuskinases pages 2-3). Subsequent phosphorylation of STAT proteins results in their dimerization and translocation into the nucleus, where they initiate transcription of genes involved in cell proliferation, differentiation, and survival (babon2014themolecularregulation pages 14-15, yeh1999thejanuskinase pages 6-8). JAK3 is critically involved in T-cell development and function, and its activity is essential for the proper maturation of T lymphocytes, natural killer (NK) cells, and B lymphocytes; deficiencies in JAK3 lead to severe combined immunodeficiency (SCID), characterized by the absence or dysfunction of these immune cell populations (yeh1999thejanuskinase pages 6-8, yamaoka2004thejanuskinases pages 1-2). Furthermore, aberrant activation or mutation of JAK3 has been implicated in various hematological malignancies and lymphoproliferative disorders, making it a clinically significant target for therapeutic intervention (raivola2018hyperactivationofoncogenic pages 2-3, tan2015developmentofselective pages 1-3).
8. Other Comments  
   Selective inhibition of JAK3 is of particular interest due to its restricted expression in immune cells and its central role in cytokine signaling; compounds such as CP-690,550 (tofacitinib) represent early examples of JAK inhibitors that target the ATP-binding site, although they are not exclusively selective for JAK3 (kim2010nsc114792anovel pages 1-2, tan2015developmentofselective pages 1-3). More recent efforts have focused on developing covalent inhibitors that exploit unique structural features of JAK3, including the presence of a conserved cysteine residue (C909) near the ATP-binding pocket, which allows for greater selectivity over other JAK family members (tan2015developmentofselective pages 3-4, forster2016selectivejak3inhibitors pages 7-7). Mutations within both the kinase and pseudokinase domains can lead to pathological outcomes; loss-of-function mutations are associated with immunodeficiency disorders such as SCID, whereas activating mutations may drive oncogenic signaling in certain leukemias (chen2000complexeffectsof pages 8-9, raivola2018hyperactivationofoncogenic pages 4-7). The therapeutic potential of targeting JAK3 is underscored by its involvement in key immune signaling pathways and by the ongoing clinical development of selective inhibitors aimed at modulating immune responses in conditions ranging from autoimmune diseases to transplant rejection (kim2010nsc114792anovel pages 13-13, babon2014themolecularregulation pages 1-3).
9. References
10. Babon, J. J., Lucet, I. S., Murphy, J. M., Nicola, N. A., & Varghese, L. N. (2014). The molecular regulation of janus kinase (jak) activation. The Biochemical Journal, 462(1), 1-13. doi:10.1042/bj20140712 (babon2014themolecularregulation pages 1-3, babon2014themolecularregulation pages 3-4, babon2014themolecularregulation pages 13-14, babon2014themolecularregulation pages 14-15).
11. Chen, M., Cheng, A., Candotti, F., Zhou, Y.-J., Hymel, A., Fasth, A., Notarangelo, L. D., & O’Shea, J. J. (2000). Complex effects of naturally occurring mutations in the jak3 pseudokinase domain: evidence for interactions between the kinase and pseudokinase domains. Molecular and Cellular Biology, 20(3), 947-956. doi:10.1128/mcb.20.3.947-956.2000 (chen2000complexeffectsof pages 1-2, chen2000complexeffectsof pages 8-9).
12. Hall, T. L. et al. (2010). Expression, purification, characterization and crystallization of non- and phosphorylated states of jak2 and jak3 kinase domain. Protein Expression and Purification, 69, 54-63. doi:10.1016/j.pep.2009.09.011 (hall2010expressionpurificationcharacterization pages 1-2, hall2010expressionpurificationcharacterization pages 10-10, hall2010expressionpurificationcharacterization pages 8-10).
13. Kim, B.-H. et al. (2010). NSC114792, a novel small molecule identified through structure-based computational database screening, selectively inhibits jak3. Molecular Cancer, 9, 36. doi:10.1186/1476-4598-9-36 (kim2010nsc114792anovel pages 1-2, kim2010nsc114792anovel pages 13-13).
14. Raivola, J., Hammarén, H. M., Virtanen, A. T., Bulleeraz, V., Ward, A. C., & Silvennoinen, O. (2018). Hyperactivation of oncogenic jak3 mutants depend on atp binding to the pseudokinase domain. Frontiers in Oncology, 8, 560. doi:10.3389/fonc.2018.00560 (raivola2018hyperactivationofoncogenic pages 1-2, raivola2018hyperactivationofoncogenic pages 2-3, raivola2018hyperactivationofoncogenic pages 4-7, raivola2018hyperactivationofoncogenic pages 8-10, raivola2018hyperactivationofoncogenic pages 12-13, raivola2018hyperactivationofoncogenic pages 13-14).
15. Tan, L. et al. (2015). Development of selective covalent janus kinase 3 inhibitors. Journal of Medicinal Chemistry, 58, 6589-6606. doi:10.1021/acs.jmedchem.5b00710 (tan2015developmentofselective pages 1-3, tan2015developmentofselective pages 3-4, tan2015developmentofselective pages 16-17).
16. Tsui, V. et al. (2011). A new regulatory switch in a jak protein kinase. Proteins: Structure, doi:10.1002/prot.22889 (tsui2011anewregulatory pages 7-8).
17. Vihinen, M. et al. (2000). Molecular modeling of the jak3 kinase domains and structural basis for severe combined immunodeficiency. Clinical Immunology, 96, 108-118. doi:10.1006/clim.2000.4880 (vihinen2000molecularmodelingof pages 3-5, vihinen2000molecularmodelingof pages 5-7, vihinen2000molecularmodelingof pages 7-9).
18. Wilks, A. F. (2008). The jak kinases: not just another kinase drug discovery target. Seminars in Cell & Developmental Biology, 19, 319-328. doi:10.1016/j.semcdb.2008.07.020 (wilks2008thejakkinases pages 1-1, wilks2008thejakkinases pages 3-4, wilks2008thejakkinases pages 4-5, wilks2008thejakkinases pages 5-6, wilks2008thejakkinases pages 8-9, wilks2008thejakkinases pages 9-9).
19. Yamaoka, K. et al. (2004). The janus kinases (jaks). Genome Biology, 5, 253. doi:10.1186/gb-2004-5-12-253 (yamaoka2004thejanuskinases pages 1-2, yamaoka2004thejanuskinases pages 2-3, yamaoka2004thejanuskinases pages 3-4, yamaoka2004thejanuskinases pages 4-5, yamaoka2004thejanuskinases pages 6-6).
20. Alicea-Velazquez, N. L. & Boggon, T. J. (2011). The use of structural biology in janus kinase targeted drug discovery. Current Drug Targets, 12, 546-555. doi:10.2174/138945011794751528 (aliceavelazquez2011theuseof pages 1-2, aliceavelazquez2011theuseof pages 2-3, aliceavelazquez2011theuseof pages 3-5, aliceavelazquez2011theuseof pages 7-8).
21. Andraos, R. et al. (2012). Modulation of activation-loop phosphorylation by jak inhibitors is binding mode dependent. Cancer Discovery, 2, 512-523. doi:10.1158/2159-8290.cd-11-0324 (andraos2012modulationofactivationloop pages 13-14).
22. Babon, J. J. et al. (2012). Suppression of cytokine signaling by socs3: characterization of the mode of inhibition and the basis of its specificity. Immunity, 36(2), 239-250. doi:10.1016/j.immuni.2011.12.015 (babon2012suppressionofcytokine pages 1-2, babon2012suppressionofcytokine pages 2-4).
23. Ferrao, R. & Lupardus, P. J. (2017). The janus kinase (jak) ferm and sh2 domains: bringing specificity to jak–receptor interactions. Frontiers in Endocrinology, 8, 71. doi:10.3389/fendo.2017.00071 (ferrao2017thejanuskinase pages 9-10).
24. Forster, M. et al. (2016). Selective jak3 inhibitors with a covalent reversible binding mode targeting a new induced fit binding pocket. Cell Chemical Biology, 23, 1335-1340. doi:10.1016/j.chembiol.2016.10.008 (forster2016selectivejak3inhibitors pages 7-7, forster2016selectivejak3inhibitors pages 5-6).
25. Glassman, C. R. et al. (2022). Structure of a janus kinase cytokine receptor complex reveals the basis for dimeric activation. Science, 376, 163-169. doi:10.1126/science.abn8933 (glassman2022structureofa pages 9-11).
26. Jiang, J.-K. et al. (2008). Examining the chirality, conformation and selective kinase inhibition of CP-690,550. Journal of Medicinal Chemistry, 51, 8012-8018. doi:10.1021/jm801142b (jiang2008examiningthechirality pages 8-10).
27. Lupardus, P. J. et al. (2014). Structure of the pseudokinase–kinase domains from protein kinase tyk2 reveals a mechanism for janus kinase (jak) autoinhibition. Proceedings of the National Academy of Sciences, 111, 8025-8030. doi:10.1073/pnas.1401180111 (lupardus2014structureofthe pages 6-6).
28. Meyer, S. C. & Levine, R. L. (2014). Molecular pathways: molecular basis for sensitivity and resistance to jak kinase inhibitors. Clinical Cancer Research, 20, 2051-2059. doi:10.1158/1078-0432.ccr-13-0279 (meyer2014molecularpathwaysmolecular pages 1-3).
29. Min, X. et al. (2015). Structural and functional characterization of the jh2 pseudokinase domain of jak family tyrosine kinase 2 (tyk2). Journal of Biological Chemistry, 290, 27261-27270. doi:10.1074/jbc.m115.672048 (min2015structuralandfunctional pages 2-3, min2015structuralandfunctional pages 6-7).
30. Silvennoinen, O. et al. (2013). New insights into the structure and function of the pseudokinase domain in jak2. Biochemical Society Transactions, 41, 1002-1007. doi:10.1042/bst20130005 (silvennoinen2013newinsightsinto pages 2-3).
31. Yeh, T. C. & Pellegrini, S. (1999). The janus kinase family of protein tyrosine kinases and their role in signaling. Cellular and Molecular Life Sciences, 55, 1523-1534. doi:10.1007/s000180050392 (yeh1999thejanuskinase pages 1-3, yeh1999thejanuskinase pages 6-8).

References

1. (babon2014themolecularregulation pages 1-3): Jeffrey J. Babon, Isabelle S. Lucet, James M. Murphy, Nicos A. Nicola, and Leila N. Varghese. The molecular regulation of janus kinase (jak) activation. The Biochemical journal, 462 1:1-13, Aug 2014. URL: https://doi.org/10.1042/bj20140712, doi:10.1042/bj20140712. This article has 412 citations.
2. (babon2014themolecularregulation pages 14-15): Jeffrey J. Babon, Isabelle S. Lucet, James M. Murphy, Nicos A. Nicola, and Leila N. Varghese. The molecular regulation of janus kinase (jak) activation. The Biochemical journal, 462 1:1-13, Aug 2014. URL: https://doi.org/10.1042/bj20140712, doi:10.1042/bj20140712. This article has 412 citations.
3. (babon2014themolecularregulation pages 4-6): Jeffrey J. Babon, Isabelle S. Lucet, James M. Murphy, Nicos A. Nicola, and Leila N. Varghese. The molecular regulation of janus kinase (jak) activation. The Biochemical journal, 462 1:1-13, Aug 2014. URL: https://doi.org/10.1042/bj20140712, doi:10.1042/bj20140712. This article has 412 citations.
4. (chen2000complexeffectsof pages 1-2): Min Chen, Alan Cheng, Fabio Candotti, Yong-Jie Zhou, Anka Hymel, Anders Fasth, Luigi D. Notarangelo, and John J. O’Shea. Complex effects of naturally occurring mutations in the jak3 pseudokinase domain: evidence for interactions between the kinase and pseudokinase domains. Molecular and Cellular Biology, 20:947-956, Feb 2000. URL: https://doi.org/10.1128/mcb.20.3.947-956.2000, doi:10.1128/mcb.20.3.947-956.2000. This article has 183 citations and is from a domain leading peer-reviewed journal.
5. (hall2010expressionpurificationcharacterization pages 1-2): Troii Hall, Thomas L. Emmons, Jill E. Chrencik, Jennifer A. Gormley, Robin A. Weinberg, Joseph W. Leone, Jeffrey L. Hirsch, Matthew J. Saabye, John F. Schindler, Jacqueline E. Day, Jennifer M. Williams, James R. Kiefer, Sandra A. Lightle, Melissa S. Harris, Siradanahalli Guru, H. David Fischer, and Alfredo G. Tomasselli. Expression, purification, characterization and crystallization of non- and phosphorylated states of jak2 and jak3 kinase domain. Protein Expression and Purification, 69:54-63, Jan 2010. URL: https://doi.org/10.1016/j.pep.2009.09.011, doi:10.1016/j.pep.2009.09.011. This article has 23 citations and is from a peer-reviewed journal.
6. (hall2010expressionpurificationcharacterization pages 10-10): Troii Hall, Thomas L. Emmons, Jill E. Chrencik, Jennifer A. Gormley, Robin A. Weinberg, Joseph W. Leone, Jeffrey L. Hirsch, Matthew J. Saabye, John F. Schindler, Jacqueline E. Day, Jennifer M. Williams, James R. Kiefer, Sandra A. Lightle, Melissa S. Harris, Siradanahalli Guru, H. David Fischer, and Alfredo G. Tomasselli. Expression, purification, characterization and crystallization of non- and phosphorylated states of jak2 and jak3 kinase domain. Protein Expression and Purification, 69:54-63, Jan 2010. URL: https://doi.org/10.1016/j.pep.2009.09.011, doi:10.1016/j.pep.2009.09.011. This article has 23 citations and is from a peer-reviewed journal.
7. (kim2010nsc114792anovel pages 1-2): Byung-Hak Kim, Jun-Goo Jee, Chang-Hong Yin, Claudio Sandoval, Somasundaram Jayabose, Daisuke Kitamura, Erika A Bach, and Gyeong-Hun Baeg. Nsc114792, a novel small molecule identified through structure-based computational database screening, selectively inhibits jak3. Molecular Cancer, 9:36-36, Feb 2010. URL: https://doi.org/10.1186/1476-4598-9-36, doi:10.1186/1476-4598-9-36. This article has 22 citations and is from a highest quality peer-reviewed journal.
8. (kim2010nsc114792anovel pages 13-13): Byung-Hak Kim, Jun-Goo Jee, Chang-Hong Yin, Claudio Sandoval, Somasundaram Jayabose, Daisuke Kitamura, Erika A Bach, and Gyeong-Hun Baeg. Nsc114792, a novel small molecule identified through structure-based computational database screening, selectively inhibits jak3. Molecular Cancer, 9:36-36, Feb 2010. URL: https://doi.org/10.1186/1476-4598-9-36, doi:10.1186/1476-4598-9-36. This article has 22 citations and is from a highest quality peer-reviewed journal.
9. (raivola2018hyperactivationofoncogenic pages 1-2): Juuli Raivola, Henrik M. Hammarén, Anniina T. Virtanen, Vilasha Bulleeraz, Alister C. Ward, and Olli Silvennoinen. Hyperactivation of oncogenic jak3 mutants depend on atp binding to the pseudokinase domain. Frontiers in Oncology, Dec 2018. URL: https://doi.org/10.3389/fonc.2018.00560, doi:10.3389/fonc.2018.00560. This article has 19 citations and is from a peer-reviewed journal.
10. (raivola2018hyperactivationofoncogenic pages 13-14): Juuli Raivola, Henrik M. Hammarén, Anniina T. Virtanen, Vilasha Bulleeraz, Alister C. Ward, and Olli Silvennoinen. Hyperactivation of oncogenic jak3 mutants depend on atp binding to the pseudokinase domain. Frontiers in Oncology, Dec 2018. URL: https://doi.org/10.3389/fonc.2018.00560, doi:10.3389/fonc.2018.00560. This article has 19 citations and is from a peer-reviewed journal.
11. (tan2015developmentofselective pages 1-3): Li Tan, Koshi Akahane, Randall McNally, Kathleen M. S. E. Reyskens, Scott B. Ficarro, Suhu Liu, Grit S. Herter-Sprie, Shohei Koyama, Michael J. Pattison, Katherine Labella, Liv Johannessen, Esra A. Akbay, Kwok-Kin Wong, David A. Frank, Jarrod A. Marto, Thomas A. Look, J. Simon C. Arthur, Michael J. Eck, and Nathanael S. Gray. Development of selective covalent janus kinase 3 inhibitors. Journal of Medicinal Chemistry, 58:6589-6606, Aug 2015. URL: https://doi.org/10.1021/acs.jmedchem.5b00710, doi:10.1021/acs.jmedchem.5b00710. This article has 121 citations and is from a highest quality peer-reviewed journal.
12. (tan2015developmentofselective pages 3-4): Li Tan, Koshi Akahane, Randall McNally, Kathleen M. S. E. Reyskens, Scott B. Ficarro, Suhu Liu, Grit S. Herter-Sprie, Shohei Koyama, Michael J. Pattison, Katherine Labella, Liv Johannessen, Esra A. Akbay, Kwok-Kin Wong, David A. Frank, Jarrod A. Marto, Thomas A. Look, J. Simon C. Arthur, Michael J. Eck, and Nathanael S. Gray. Development of selective covalent janus kinase 3 inhibitors. Journal of Medicinal Chemistry, 58:6589-6606, Aug 2015. URL: https://doi.org/10.1021/acs.jmedchem.5b00710, doi:10.1021/acs.jmedchem.5b00710. This article has 121 citations and is from a highest quality peer-reviewed journal.
13. (tsui2011anewregulatory pages 7-8): Vickie Tsui, Paul Gibbons, Mark Ultsch, Kyle Mortara, Christine Chang, Wade Blair, Rebecca Pulk, Mark Stanley, Melissa Starovasnik, David Williams, Maria Lamers, Phillip Leonard, Steven Magnuson, Jun Liang, and Charles Eigenbrot. A new regulatory switch in a jak protein kinase. Proteins: Structure, Feb 2011. URL: https://doi.org/10.1002/prot.22889, doi:10.1002/prot.22889. This article has 34 citations.
14. (vihinen2000molecularmodelingof pages 3-5): Mauno Vihinen, Anna Villa, Patrizia Mella, R.Fabian Schumacher, Gianfranco Savoldi, John J. O’Shea, Fabio Candotti, and Luigi D. Notarangelo. Molecular modeling of the jak3 kinase domains and structural basis for severe combined immunodeficiency. Clinical Immunology, 96:108-118, Aug 2000. URL: https://doi.org/10.1006/clim.2000.4880, doi:10.1006/clim.2000.4880. This article has 36 citations and is from a peer-reviewed journal.
15. (vihinen2000molecularmodelingof pages 5-7): Mauno Vihinen, Anna Villa, Patrizia Mella, R.Fabian Schumacher, Gianfranco Savoldi, John J. O’Shea, Fabio Candotti, and Luigi D. Notarangelo. Molecular modeling of the jak3 kinase domains and structural basis for severe combined immunodeficiency. Clinical Immunology, 96:108-118, Aug 2000. URL: https://doi.org/10.1006/clim.2000.4880, doi:10.1006/clim.2000.4880. This article has 36 citations and is from a peer-reviewed journal.
16. (wilks2008thejakkinases pages 4-5): Andrew F. Wilks. The jak kinases: not just another kinase drug discovery target. Seminars in Cell & Developmental Biology, 19:319-328, Aug 2008. URL: https://doi.org/10.1016/j.semcdb.2008.07.020, doi:10.1016/j.semcdb.2008.07.020. This article has 122 citations.
17. (wilks2008thejakkinases pages 5-6): Andrew F. Wilks. The jak kinases: not just another kinase drug discovery target. Seminars in Cell & Developmental Biology, 19:319-328, Aug 2008. URL: https://doi.org/10.1016/j.semcdb.2008.07.020, doi:10.1016/j.semcdb.2008.07.020. This article has 122 citations.
18. (wilks2008thejakkinases pages 8-9): Andrew F. Wilks. The jak kinases: not just another kinase drug discovery target. Seminars in Cell & Developmental Biology, 19:319-328, Aug 2008. URL: https://doi.org/10.1016/j.semcdb.2008.07.020, doi:10.1016/j.semcdb.2008.07.020. This article has 122 citations.
19. (wilks2008thejakkinases pages 9-9): Andrew F. Wilks. The jak kinases: not just another kinase drug discovery target. Seminars in Cell & Developmental Biology, 19:319-328, Aug 2008. URL: https://doi.org/10.1016/j.semcdb.2008.07.020, doi:10.1016/j.semcdb.2008.07.020. This article has 122 citations.
20. (yamaoka2004thejanuskinases pages 2-3): Kunihiro Yamaoka, Pipsa Saharinen, Marko Pesu, Vance ET Holt, Olli Silvennoinen, and John J O’Shea. The janus kinases (jaks). Genome Biology, 5:253-253, Nov 2004. URL: https://doi.org/10.1186/gb-2004-5-12-253, doi:10.1186/gb-2004-5-12-253. This article has 848 citations and is from a highest quality peer-reviewed journal.
21. (yamaoka2004thejanuskinases pages 3-4): Kunihiro Yamaoka, Pipsa Saharinen, Marko Pesu, Vance ET Holt, Olli Silvennoinen, and John J O’Shea. The janus kinases (jaks). Genome Biology, 5:253-253, Nov 2004. URL: https://doi.org/10.1186/gb-2004-5-12-253, doi:10.1186/gb-2004-5-12-253. This article has 848 citations and is from a highest quality peer-reviewed journal.
22. (yamaoka2004thejanuskinases pages 4-5): Kunihiro Yamaoka, Pipsa Saharinen, Marko Pesu, Vance ET Holt, Olli Silvennoinen, and John J O’Shea. The janus kinases (jaks). Genome Biology, 5:253-253, Nov 2004. URL: https://doi.org/10.1186/gb-2004-5-12-253, doi:10.1186/gb-2004-5-12-253. This article has 848 citations and is from a highest quality peer-reviewed journal.
23. (aliceavelazquez2011theuseof pages 1-2): Nilda L. Alicea-Velazquez and Titus J. Boggon. The use of structural biology in janus kinase targeted drug discovery. Current Drug Targets, 12:546-555, Apr 2011. URL: https://doi.org/10.2174/138945011794751528, doi:10.2174/138945011794751528. This article has 65 citations and is from a peer-reviewed journal.
24. (aliceavelazquez2011theuseof pages 2-3): Nilda L. Alicea-Velazquez and Titus J. Boggon. The use of structural biology in janus kinase targeted drug discovery. Current Drug Targets, 12:546-555, Apr 2011. URL: https://doi.org/10.2174/138945011794751528, doi:10.2174/138945011794751528. This article has 65 citations and is from a peer-reviewed journal.
25. (aliceavelazquez2011theuseof pages 3-5): Nilda L. Alicea-Velazquez and Titus J. Boggon. The use of structural biology in janus kinase targeted drug discovery. Current Drug Targets, 12:546-555, Apr 2011. URL: https://doi.org/10.2174/138945011794751528, doi:10.2174/138945011794751528. This article has 65 citations and is from a peer-reviewed journal.
26. (aliceavelazquez2011theuseof pages 7-8): Nilda L. Alicea-Velazquez and Titus J. Boggon. The use of structural biology in janus kinase targeted drug discovery. Current Drug Targets, 12:546-555, Apr 2011. URL: https://doi.org/10.2174/138945011794751528, doi:10.2174/138945011794751528. This article has 65 citations and is from a peer-reviewed journal.
27. (andraos2012modulationofactivationloop pages 13-14): Rita Andraos, Zhiyan Qian, Débora Bonenfant, Joëlle Rubert, Eric Vangrevelinghe, Clemens Scheufler, Fanny Marque, Catherine H. Régnier, Alain De Pover, Hugues Ryckelynck, Neha Bhagwat, Priya Koppikar, Aviva Goel, Lorenza Wyder, Gisele Tavares, Fabienne Baffert, Carole Pissot-Soldermann, Paul W. Manley, Christoph Gaul, Hans Voshol, Ross L. Levine, William R. Sellers, Francesco Hofmann, and Thomas Radimerski. Modulation of activation-loop phosphorylation by jak inhibitors is binding mode dependent. Cancer Discovery, 2:512-523, Jun 2012. URL: https://doi.org/10.1158/2159-8290.cd-11-0324, doi:10.1158/2159-8290.cd-11-0324. This article has 156 citations and is from a highest quality peer-reviewed journal.
28. (babon2012suppressionofcytokine pages 1-2): Jeffrey J. Babon, Nadia J. Kershaw, James M. Murphy, Leila N. Varghese, Artem Laktyushin, Samuel N. Young, Isabelle S. Lucet, Raymond S. Norton, and Nicos A. Nicola. Suppression of cytokine signaling by socs3: characterization of the mode of inhibition and the basis of its specificity. Immunity, 36 2:239-50, Feb 2012. URL: https://doi.org/10.1016/j.immuni.2011.12.015, doi:10.1016/j.immuni.2011.12.015. This article has 341 citations and is from a highest quality peer-reviewed journal.
29. (babon2012suppressionofcytokine pages 2-4): Jeffrey J. Babon, Nadia J. Kershaw, James M. Murphy, Leila N. Varghese, Artem Laktyushin, Samuel N. Young, Isabelle S. Lucet, Raymond S. Norton, and Nicos A. Nicola. Suppression of cytokine signaling by socs3: characterization of the mode of inhibition and the basis of its specificity. Immunity, 36 2:239-50, Feb 2012. URL: https://doi.org/10.1016/j.immuni.2011.12.015, doi:10.1016/j.immuni.2011.12.015. This article has 341 citations and is from a highest quality peer-reviewed journal.
30. (babon2014themolecularregulation pages 13-14): Jeffrey J. Babon, Isabelle S. Lucet, James M. Murphy, Nicos A. Nicola, and Leila N. Varghese. The molecular regulation of janus kinase (jak) activation. The Biochemical journal, 462 1:1-13, Aug 2014. URL: https://doi.org/10.1042/bj20140712, doi:10.1042/bj20140712. This article has 412 citations.
31. (babon2014themolecularregulation pages 3-4): Jeffrey J. Babon, Isabelle S. Lucet, James M. Murphy, Nicos A. Nicola, and Leila N. Varghese. The molecular regulation of janus kinase (jak) activation. The Biochemical journal, 462 1:1-13, Aug 2014. URL: https://doi.org/10.1042/bj20140712, doi:10.1042/bj20140712. This article has 412 citations.
32. (chen2000complexeffectsof pages 8-9): Min Chen, Alan Cheng, Fabio Candotti, Yong-Jie Zhou, Anka Hymel, Anders Fasth, Luigi D. Notarangelo, and John J. O’Shea. Complex effects of naturally occurring mutations in the jak3 pseudokinase domain: evidence for interactions between the kinase and pseudokinase domains. Molecular and Cellular Biology, 20:947-956, Feb 2000. URL: https://doi.org/10.1128/mcb.20.3.947-956.2000, doi:10.1128/mcb.20.3.947-956.2000. This article has 183 citations and is from a domain leading peer-reviewed journal.
33. (ferrao2017thejanuskinase pages 9-10): Ryan Ferrao and Patrick J. Lupardus. The janus kinase (jak) ferm and sh2 domains: bringing specificity to jak–receptor interactions. Frontiers in Endocrinology, Apr 2017. URL: https://doi.org/10.3389/fendo.2017.00071, doi:10.3389/fendo.2017.00071. This article has 148 citations and is from a peer-reviewed journal.
34. (forster2016selectivejak3inhibitors pages 7-7): Michael Forster, Apirat Chaikuad, Silke M. Bauer, Julia Holstein, Matthew B. Robers, Cesear R. Corona, Matthias Gehringer, Ellen Pfaffenrot, Kamran Ghoreschi, Stefan Knapp, and Stefan A. Laufer. Selective jak3 inhibitors with a covalent reversible binding mode targeting a new induced fit binding pocket. Cell Chemical Biology, 23:1335-1340, Nov 2016. URL: https://doi.org/10.1016/j.chembiol.2016.10.008, doi:10.1016/j.chembiol.2016.10.008. This article has 122 citations and is from a domain leading peer-reviewed journal.
35. (glassman2022structureofa pages 9-11): Caleb R. Glassman, Naotaka Tsutsumi, Robert A. Saxton, Patrick J. Lupardus, Kevin M. Jude, and K. Christopher Garcia. Structure of a janus kinase cytokine receptor complex reveals the basis for dimeric activation. Science, 376:163-169, Apr 2022. URL: https://doi.org/10.1126/science.abn8933, doi:10.1126/science.abn8933. This article has 130 citations and is from a highest quality peer-reviewed journal.
36. (hall2010expressionpurificationcharacterization pages 8-10): Troii Hall, Thomas L. Emmons, Jill E. Chrencik, Jennifer A. Gormley, Robin A. Weinberg, Joseph W. Leone, Jeffrey L. Hirsch, Matthew J. Saabye, John F. Schindler, Jacqueline E. Day, Jennifer M. Williams, James R. Kiefer, Sandra A. Lightle, Melissa S. Harris, Siradanahalli Guru, H. David Fischer, and Alfredo G. Tomasselli. Expression, purification, characterization and crystallization of non- and phosphorylated states of jak2 and jak3 kinase domain. Protein Expression and Purification, 69:54-63, Jan 2010. URL: https://doi.org/10.1016/j.pep.2009.09.011, doi:10.1016/j.pep.2009.09.011. This article has 23 citations and is from a peer-reviewed journal.
37. (jiang2008examiningthechirality pages 8-10): Jian-kang Jiang, Kamran Ghoreschi, Francesca Deflorian, Zhi Chen, Melissa Perreira, Marko Pesu, Jeremy Smith, Dac-Trung Nguyen, Eric H. Liu, William Leister, Stefano Costanzi, John J. O’Shea, and Craig J. Thomas. Examining the chirality, conformation and selective kinase inhibition of 3-((3r,4r)-4-methyl-3-(methyl(7h-pyrrolo[2,3-d]pyrimidin-4-yl)amino)piperidin-1-yl)-3-oxopropanenitrile (cp-690,550). Journal of medicinal chemistry, 51 24:8012-8, Dec 2008. URL: https://doi.org/10.1021/jm801142b, doi:10.1021/jm801142b. This article has 146 citations and is from a highest quality peer-reviewed journal.
38. (lupardus2014structureofthe pages 6-6): Patrick J. Lupardus, Mark Ultsch, Heidi Wallweber, Pawan Bir Kohli, Adam R. Johnson, and Charles Eigenbrot. Structure of the pseudokinase–kinase domains from protein kinase tyk2 reveals a mechanism for janus kinase (jak) autoinhibition. Proceedings of the National Academy of Sciences, 111:8025-8030, May 2014. URL: https://doi.org/10.1073/pnas.1401180111, doi:10.1073/pnas.1401180111. This article has 228 citations.
39. (meyer2014molecularpathwaysmolecular pages 1-3): Sara C. Meyer and Ross L. Levine. Molecular pathways: molecular basis for sensitivity and resistance to jak kinase inhibitors. Clinical Cancer Research, 20:2051-2059, Apr 2014. URL: https://doi.org/10.1158/1078-0432.ccr-13-0279, doi:10.1158/1078-0432.ccr-13-0279. This article has 195 citations and is from a highest quality peer-reviewed journal.
40. (raivola2018hyperactivationofoncogenic pages 12-13): Juuli Raivola, Henrik M. Hammarén, Anniina T. Virtanen, Vilasha Bulleeraz, Alister C. Ward, and Olli Silvennoinen. Hyperactivation of oncogenic jak3 mutants depend on atp binding to the pseudokinase domain. Frontiers in Oncology, Dec 2018. URL: https://doi.org/10.3389/fonc.2018.00560, doi:10.3389/fonc.2018.00560. This article has 19 citations and is from a peer-reviewed journal.
41. (raivola2018hyperactivationofoncogenic pages 2-3): Juuli Raivola, Henrik M. Hammarén, Anniina T. Virtanen, Vilasha Bulleeraz, Alister C. Ward, and Olli Silvennoinen. Hyperactivation of oncogenic jak3 mutants depend on atp binding to the pseudokinase domain. Frontiers in Oncology, Dec 2018. URL: https://doi.org/10.3389/fonc.2018.00560, doi:10.3389/fonc.2018.00560. This article has 19 citations and is from a peer-reviewed journal.
42. (raivola2018hyperactivationofoncogenic pages 4-7): Juuli Raivola, Henrik M. Hammarén, Anniina T. Virtanen, Vilasha Bulleeraz, Alister C. Ward, and Olli Silvennoinen. Hyperactivation of oncogenic jak3 mutants depend on atp binding to the pseudokinase domain. Frontiers in Oncology, Dec 2018. URL: https://doi.org/10.3389/fonc.2018.00560, doi:10.3389/fonc.2018.00560. This article has 19 citations and is from a peer-reviewed journal.
43. (raivola2018hyperactivationofoncogenic pages 8-10): Juuli Raivola, Henrik M. Hammarén, Anniina T. Virtanen, Vilasha Bulleeraz, Alister C. Ward, and Olli Silvennoinen. Hyperactivation of oncogenic jak3 mutants depend on atp binding to the pseudokinase domain. Frontiers in Oncology, Dec 2018. URL: https://doi.org/10.3389/fonc.2018.00560, doi:10.3389/fonc.2018.00560. This article has 19 citations and is from a peer-reviewed journal.
44. (silvennoinen2013newinsightsinto pages 2-3): Olli Silvennoinen, Daniela Ungureanu, Yashavanthi Niranjan, Henrik Hammaren, Rajintha Bandaranayake, and Stevan R. Hubbard. New insights into the structure and function of the pseudokinase domain in jak2. Biochemical Society transactions, 41 4:1002-7, Aug 2013. URL: https://doi.org/10.1042/bst20130005, doi:10.1042/bst20130005. This article has 62 citations and is from a peer-reviewed journal.
45. (tan2015developmentofselective pages 16-17): Li Tan, Koshi Akahane, Randall McNally, Kathleen M. S. E. Reyskens, Scott B. Ficarro, Suhu Liu, Grit S. Herter-Sprie, Shohei Koyama, Michael J. Pattison, Katherine Labella, Liv Johannessen, Esra A. Akbay, Kwok-Kin Wong, David A. Frank, Jarrod A. Marto, Thomas A. Look, J. Simon C. Arthur, Michael J. Eck, and Nathanael S. Gray. Development of selective covalent janus kinase 3 inhibitors. Journal of Medicinal Chemistry, 58:6589-6606, Aug 2015. URL: https://doi.org/10.1021/acs.jmedchem.5b00710, doi:10.1021/acs.jmedchem.5b00710. This article has 121 citations and is from a highest quality peer-reviewed journal.
46. (vihinen2000molecularmodelingof pages 7-9): Mauno Vihinen, Anna Villa, Patrizia Mella, R.Fabian Schumacher, Gianfranco Savoldi, John J. O’Shea, Fabio Candotti, and Luigi D. Notarangelo. Molecular modeling of the jak3 kinase domains and structural basis for severe combined immunodeficiency. Clinical Immunology, 96:108-118, Aug 2000. URL: https://doi.org/10.1006/clim.2000.4880, doi:10.1006/clim.2000.4880. This article has 36 citations and is from a peer-reviewed journal.
47. (wilks2008thejakkinases pages 1-1): Andrew F. Wilks. The jak kinases: not just another kinase drug discovery target. Seminars in Cell & Developmental Biology, 19:319-328, Aug 2008. URL: https://doi.org/10.1016/j.semcdb.2008.07.020, doi:10.1016/j.semcdb.2008.07.020. This article has 122 citations.
48. (wilks2008thejakkinases pages 3-4): Andrew F. Wilks. The jak kinases: not just another kinase drug discovery target. Seminars in Cell & Developmental Biology, 19:319-328, Aug 2008. URL: https://doi.org/10.1016/j.semcdb.2008.07.020, doi:10.1016/j.semcdb.2008.07.020. This article has 122 citations.
49. (yamaoka2004thejanuskinases pages 1-2): Kunihiro Yamaoka, Pipsa Saharinen, Marko Pesu, Vance ET Holt, Olli Silvennoinen, and John J O’Shea. The janus kinases (jaks). Genome Biology, 5:253-253, Nov 2004. URL: https://doi.org/10.1186/gb-2004-5-12-253, doi:10.1186/gb-2004-5-12-253. This article has 848 citations and is from a highest quality peer-reviewed journal.
50. (yeh1999thejanuskinase pages 1-3): T. C. Yeh and S. Pellegrini. The janus kinase family of protein tyrosine kinases and their role in signaling. Cellular and Molecular Life Sciences (CMLS), 55:1523-1534, Oct 1999. URL: https://doi.org/10.1007/s000180050392, doi:10.1007/s000180050392. This article has 165 citations.
51. (yeh1999thejanuskinase pages 6-8): T. C. Yeh and S. Pellegrini. The janus kinase family of protein tyrosine kinases and their role in signaling. Cellular and Molecular Life Sciences (CMLS), 55:1523-1534, Oct 1999. URL: https://doi.org/10.1007/s000180050392, doi:10.1007/s000180050392. This article has 165 citations.
52. (forster2016selectivejak3inhibitors pages 5-6): Michael Forster, Apirat Chaikuad, Silke M. Bauer, Julia Holstein, Matthew B. Robers, Cesear R. Corona, Matthias Gehringer, Ellen Pfaffenrot, Kamran Ghoreschi, Stefan Knapp, and Stefan A. Laufer. Selective jak3 inhibitors with a covalent reversible binding mode targeting a new induced fit binding pocket. Cell Chemical Biology, 23:1335-1340, Nov 2016. URL: https://doi.org/10.1016/j.chembiol.2016.10.008, doi:10.1016/j.chembiol.2016.10.008. This article has 122 citations and is from a domain leading peer-reviewed journal.
53. (min2015structuralandfunctional pages 2-3): Xiaoshan Min, Daniela Ungureanu, Sarah Maxwell, Henrik Hammarén, Steve Thibault, Ellin-Kristina Hillert, Merrill Ayres, Brad Greenfield, John Eksterowicz, Chris Gabel, Nigel Walker, Olli Silvennoinen, and Zhulun Wang. Structural and functional characterization of the jh2 pseudokinase domain of jak family tyrosine kinase 2 (tyk2). Journal of Biological Chemistry, 290:27261-27270, Nov 2015. URL: https://doi.org/10.1074/jbc.m115.672048, doi:10.1074/jbc.m115.672048. This article has 108 citations and is from a domain leading peer-reviewed journal.
54. (min2015structuralandfunctional pages 6-7): Xiaoshan Min, Daniela Ungureanu, Sarah Maxwell, Henrik Hammarén, Steve Thibault, Ellin-Kristina Hillert, Merrill Ayres, Brad Greenfield, John Eksterowicz, Chris Gabel, Nigel Walker, Olli Silvennoinen, and Zhulun Wang. Structural and functional characterization of the jh2 pseudokinase domain of jak family tyrosine kinase 2 (tyk2). Journal of Biological Chemistry, 290:27261-27270, Nov 2015. URL: https://doi.org/10.1074/jbc.m115.672048, doi:10.1074/jbc.m115.672048. This article has 108 citations and is from a domain leading peer-reviewed journal.
55. (yamaoka2004thejanuskinases pages 6-6): Kunihiro Yamaoka, Pipsa Saharinen, Marko Pesu, Vance ET Holt, Olli Silvennoinen, and John J O’Shea. The janus kinases (jaks). Genome Biology, 5:253-253, Nov 2004. URL: https://doi.org/10.1186/gb-2004-5-12-253, doi:10.1186/gb-2004-5-12-253. This article has 848 citations and is from a highest quality peer-reviewed journal.